Cancer is a complex disease driven by somatic mutations accumulating within cells.  Recent advances in genomics have significantly improved our understanding of the genetic basis of cancer, revealing diverse driver mutations across various cancer types. This knowledge fuels the development of personalized medicine approaches tailored to individual tumor profiles. Next-generation sequencing technologies enable comprehensive genomic profiling, identifying actionable mutations that guide targeted therapies, such as tyrosine kinase inhibitors for specific oncogenic mutations or immune checkpoint inhibitors for tumors with high mutational burdens.  Furthermore, the identification of biomarkers predictive of treatment response allows for patient stratification and optimized therapeutic strategies. However, challenges remain, including the identification of novel therapeutic targets, the complexities of intratumoral heterogeneity, and the cost and accessibility of genomic testing.  Ongoing research focuses on improving the accuracy and efficiency of genomic profiling, developing novel therapeutic agents targeting less common mutations, and integrating genomic data with other clinical parameters to refine personalized cancer treatment plans and enhance patient outcomes.  The continued integration of genomics into clinical practice promises a future of more effective and precise cancer therapies.